v3.26.1
Segment Information
 12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company operates as a single reportable and single operating segment in the development of the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The Company has not generated revenues since inception. The Company’s chief operating decision maker (“CODM”) is its chief executive officer. The CODM reviews financial information on a basis consistent with the information presented in the financial statements for purposes of making operating decisions, allocating resources, and evaluating financial performance. The Company’s CODM uses operating loss as the measure to evaluate the segment’s operating performance and to monitor budgeted to actual expenditures associated with capital projects. The measure of segment assets is reported on the Company’s balance sheets as total assets.
Significant segment expenses and other segment items are reviewed by the CODM on a disaggregated basis as follows:
Year Ended December 31,
(in thousands)20252024
Salaries and benefits$11,762 $7,203 
Stock-based compensation2,786 1,489 
Professional fees6,248 1,517 
Marketing expense1,003 205 
Lead product project expenses15,918 14,208 
Rental and facilities expense1,655 1,360 
Other segment items (1)
497 3,182 
Net loss and comprehensive loss$39,869 $29,164 
(1)Other segment items primarily consist of costs associated with early-stage research and development programs, business travel and state related taxes, interest income and the change in fair value of redeemable convertible preferred stock tranche liability.